MNPR
Monopar Therapeutics Inc.
Biotechnology
Market Cap$416M
5Y Perf.+62.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNPR vs ADXN
Revenue, margins, valuation, and 5-year total return — side by side.
ADXN
Addex Therapeutics Ltd
Biotechnology
Market Cap$5M
5Y Perf.-95.2%
MNPR vs ADXN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNPR | ADXN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $416M | $5M |
| Revenue (TTM) | $0.00 | $68K |
| Net Income (TTM) | $-19M | $-6M |
| Gross Margin | — | -246.8% |
| Operating Margin | — | -36.7% |
| Forward P/E | — | 0.7x |
| Total Debt | $0.00 | $42K |
| Cash & Equiv. | $46M | $3M |
MNPR vs ADXN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNPR
ADXN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Monopar Therapeutic… (MNPR) | 100 | 162.2 | +62.2% |
| Addex Therapeutics … (ADXN) | 100 | 4.8 | -95.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNPR vs ADXN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNPR leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Addex Therapeutics Ltd is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MNPR
Monopar Therapeutics Inc.
The Long-Run Compounder
MNPR carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -52.9% 10Y total return vs ADXN's -96.9%
- 1.9K% revenue growth vs ADXN's -74.9%
- 0.7% margin vs ADXN's -90.2%
Best for: long-term compounding
ADXN
Addex Therapeutics Ltd
The Income Pick
ADXN is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.59
- Rev growth -74.9%, EPS growth 150.0%, 3Y rev CAGR -48.3%
- Lower volatility, beta 0.59, Low D/E 0.4%, current ratio 4.42x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNPR | 1.9K% revenue growth vs ADXN's -74.9% |
| Quality / Margins | MNPR | 0.7% margin vs ADXN's -90.2% |
| Stability / Safety | ADXN | Beta 0.59 vs MNPR's 1.46 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNPR | +59.7% vs ADXN's -13.1% |
| Efficiency (ROA) | MNPR | -24.8% ROA vs ADXN's -67.7%, ROIC -321.4% vs -103.3% |
MNPR vs ADXN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MNPR vs ADXN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNPRLAGGINGADXN
ADXNAddex Therapeutics Ltd
1leads
MNPRMonopar Therapeutics …
2leads
6 Total Categories
CATEGORYLEADERvs ADXNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ADXN1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNPR4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MNPR6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ADXN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ADXN and MNPR operate at a comparable scale, with $67,607 and $0 in trailing revenue.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $67,607 |
| EBITDAEarnings before interest/tax | -$20M | -$2M |
| Net IncomeAfter-tax profit | -$19M | -$6M |
| Free Cash FlowCash after capex | -$11M | -$2M |
| Gross MarginGross profit ÷ Revenue | — | -2.5% |
| Operating MarginEBIT ÷ Revenue | — | -36.7% |
| Net MarginNet income ÷ Revenue | — | -90.2% |
| FCF MarginFCF ÷ Revenue | — | -23.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -44.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +11.2% |
ADXN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MNPR and ADXN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| Market CapShares × price | $416M | $5M |
| Enterprise ValueMkt cap + debt − cash | $370M | $394,716 |
| Trailing P/EPrice ÷ TTM EPS | -45.90x | 0.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 8.93x |
| Price / BookPrice ÷ Book value/share | 13.03x | 0.46x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MNPR and ADXN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNPR leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
MNPR delivers a -25.7% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-78 for ADXN.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | -78.3% |
| ROA (TTM)Return on assets | -24.8% | -67.7% |
| ROICReturn on invested capital | -3.2% | -103.3% |
| ROCEReturn on capital employed | -53.3% | -47.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$46M | -$3M |
| Cash & Equiv.Liquid assets | $46M | $3M |
| Total DebtShort + long-term debt | $0 | $41,994 |
| Interest CoverageEBIT ÷ Interest expense | — | -1857.72x |
MNPR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MNPR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNPR five years ago would be worth $23,648 today (with dividends reinvested), compared to $354 for ADXN. Over the past 12 months, MNPR leads with a +59.7% total return vs ADXN's -13.1%. The 3-year compound annual growth rate (CAGR) favors MNPR at 132.0% vs ADXN's -21.7% — a key indicator of consistent wealth creation.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -5.4% | -13.3% |
| 1-Year ReturnPast 12 months | +59.7% | -13.1% |
| 3-Year ReturnCumulative with dividends | +1148.6% | -52.0% |
| 5-Year ReturnCumulative with dividends | +136.5% | -96.5% |
| 10-Year ReturnCumulative with dividends | -52.9% | -96.9% |
| CAGR (3Y)Annualised 3-year return | +132.0% | -21.7% |
MNPR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNPR and ADXN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADXN is the less volatile stock with a 0.59 beta — it tends to amplify market swings less than MNPR's 1.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 0.59x |
| 52-Week HighHighest price in past year | $105.00 | $12.05 |
| 52-Week LowLowest price in past year | $28.40 | $5.41 |
| % of 52W HighCurrent price vs 52-week peak | +59.5% | +58.2% |
| RSI (14)Momentum oscillator 0–100 | 68.1 | 51.3 |
| Avg Volume (50D)Average daily shares traded | 173K | 4K |
Evenly matched — MNPR and ADXN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $119.00 | — |
| # AnalystsCovering analysts | 13 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNPR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ADXN leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMonopar Therapeutics Inc. (MNPR)Leads 2 of 6 categories
Loading custom metrics...
MNPR vs ADXN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNPR or ADXN a better buy right now?
Addex Therapeutics Ltd (ADXN) offers the better valuation at 0.
7x trailing P/E, making it the more compelling value choice. Analysts rate Monopar Therapeutics Inc. (MNPR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNPR or ADXN?
Over the past 5 years, Monopar Therapeutics Inc.
(MNPR) delivered a total return of +136. 5%, compared to -96. 5% for Addex Therapeutics Ltd (ADXN). Over 10 years, the gap is even starker: MNPR returned -52. 9% versus ADXN's -96. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNPR or ADXN?
By beta (market sensitivity over 5 years), Addex Therapeutics Ltd (ADXN) is the lower-risk stock at 0.
59β versus Monopar Therapeutics Inc. 's 1. 46β — meaning MNPR is approximately 148% more volatile than ADXN relative to the S&P 500.
04Which is growing faster — MNPR or ADXN?
On earnings-per-share growth, the picture is similar: Addex Therapeutics Ltd grew EPS 150.
0% year-over-year, compared to -134. 5% for Monopar Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNPR or ADXN?
Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus 0.
0% for Monopar Therapeutics Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNPR leads at 0. 0% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNPR or ADXN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNPR or ADXN better for a retirement portfolio?
For long-horizon retirement investors, Addex Therapeutics Ltd (ADXN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
59)). Both have compounded well over 10 years (ADXN: -96. 9%, MNPR: -52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNPR and ADXN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MNPR is a small-cap quality compounder stock; ADXN is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.